Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19

ESC Heart Fail. 2020 Oct;7(5):3119-3123. doi: 10.1002/ehf2.12952. Epub 2020 Jul 28.

Abstract

The present Perspective examined the latest evidence on the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID-19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice-changing guidelines.

Keywords: Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitor; COVID-19; Mortality; Severity.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Angiotensin Receptor Antagonists / adverse effects*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • COVID-19
  • Cause of Death
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / mortality
  • Female
  • Hospital Mortality / trends
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Pandemics / statistics & numerical data*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / mortality
  • Prognosis
  • Risk Assessment
  • Severe Acute Respiratory Syndrome / drug therapy
  • Severe Acute Respiratory Syndrome / mortality*
  • Survival Analysis

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors